Global law firm Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Grünenthal Pharma GmbH & Co. KG (‘Grünenthal’) on a €500 million amend and extend financing transaction. The financing is provided by an international banking syndicate and the transaction provides for an upsize and extension of Grünenthal’s existing revolving credit facility.
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, it has a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the US. Its products are available in approximately 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved stand-alone sales of approximately €1.7 billion.
Freshfields advised Grünenthal on all legal aspects of the transaction.
The team comprised Partners Frank Laudenklos and Michael Josenhans, Counsel Alexander Pospisil and Associates Lucas Lengersdorf and Alexander Bräuer (all Finance, Frankfurt). Freshfields worked closely again with the legal team at Grünenthal led by Sebastian Köhler (General Counsel) and including Sabine König (Senior Legal Counsel).
